Globus Medical, Inc. $GMED Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its position in shares of Globus Medical, Inc. (NYSE:GMED) by 71,618.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 716,469 shares of the medical device company’s stock after acquiring an additional 715,470 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Globus Medical were worth $62,555,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC grew its stake in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. SBI Securities Co. Ltd. grew its stake in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. First Horizon Corp acquired a new position in shares of Globus Medical in the 3rd quarter valued at $31,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GMED has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Barclays lifted their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Needham & Company LLC lifted their price target on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.36.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 18.38% of the stock is owned by company insiders.

Globus Medical Trading Down 0.2%

NYSE:GMED opened at $76.52 on Monday. The firm has a market capitalization of $10.39 billion, a price-to-earnings ratio of 17.79, a PEG ratio of 1.58 and a beta of 1.00. The firm’s fifty day simple moving average is $87.78 and its 200 day simple moving average is $87.25. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.